Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Technology ID
TAB-4285

Molecular Nanotags for Detection of Single Molecules

E-Numbers
E-238-2015-0
Lead Inventors
Jones, Jennifer
Co-Inventors
Telford, William
Applications
Research Materials
Therapeutic Areas
Oncology
Infectious Disease
Endocrinology
Development Stages
Discovery
Lead IC
NCI
ICs
NCI

Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity.

Researchers at the National Cancer Institute (NCI) developed a new class of nanoscale molecular tags (nanotags) allowing the detection and sorting of single biological nanoparticle using conventional flow cytometers. Otherwise, using standard methods such as fluorescently labeled antibodies, very few epitopes are detected. These nanotags are composed of materials with high refractive indices, high optical absorption, and remarkable spectral scattering properties. These properties allow both low epitope number determination and spectral phenotyping of biological nanoparticles – such as EVs, lipoproteins, RNA-protein complexes and other circulating submicron particles with significant biomedical applications.

The NCI seeks commercial partners to co-develop and/or license this technology.

Competitive Advantages:

  • Detect, sort and analyze nanomaterials <200 nanometers with single epitope sensitivity 
  • Enumeration of the number of labeled molecules beyond the capabilities of current flow cytometric labels and instruments
  • Improved detection above background noise
  • Improved signal:noise ratio 

 

Commercial Applications:

  • Research tool for studying structure and function of biological nanoparticles
  • Diagnostic tool for detection of clinical biomarkers 
  • Tool for characterization of industrial and environmental nanoparticles
  • Biodefense
  • Industrial sectors
  • Environmental applications
Licensing Contacts
Pollard, Ricquita
ricquita.pollard@nih.gov